[Skip to Navigation]
Sign In
In This Issue of JAMA Oncology
February 2020


JAMA Oncol. 2020;6(2):171. doi:10.1001/jamaoncol.2019.4202


Geriatric Assessment in Older Patients With Cancer

Mohile and colleagues performed a cluster-randomized clinical trial that enrolled 541 participants 70 years or older from 31 community oncology practices. Practices were randomized to receive a geriatric assessment summary with recommendations for each patient (intervention) or alerts only for patients with depression or cognitive impairment (usual care). The findings suggest that use of a geriatric assessment improves communication about aging-related concerns. Biganzoli and colleagues provide an Invited Commentary.

Invited Commentary

This meta-analysis by Terrisse and colleagues for the MORPHEP Collaborative Group compared bone-targeted radioisotope use with no radioisotope use among 2081 patients with castration-resistant prostate cancer. The analysis showed a significant improvement in overall survival and symptomatic skeletal free-survival with bone-targeted α-emitting, but not β-emitting, radioisotopes. Swami and colleagues provide an Invited Commentary.

Invited Commentary

In this observational cohort study, Calkins and colleagues evaluated the association of CD4 count and HIV RNA level with all-cause mortality after cancer treatment in 196 patients with HIV. Chemotherapy and/or radiotherapy was associated with significantly decreased initial CD4 count compared with surgery or other treatment. Lower CD4 count after cancer treatment was associated with an increased hazard of mortality. Bender Ignacio and colleagues provide an Invited Commentary.

Invited Commentary

This cohort study by Bird and colleagues compared treatment outcomes in clinical trial participants 65 years or older vs Medicare beneficiaries who received treatment with idelalisib for follicular lymphoma or idelalisib plus rituximab for chronic lymphocytic leukemia. The authors observed substantial imbalances in baseline comorbidities and treatment outcomes between Medicare beneficiaries and trial participants, which may limit generalizability of trial data for this agent to clinical practice.